Cell Therapy Brings Hope in Deadly Brain Cancer Case

Published on: LinkedIn (Spencer Knight)

A groundbreaking case in glioblastoma treatment has emerged from a U.S. clinical trial. Pamela Goldberger, 65, diagnosed in 2023 with a brain cancer carrying an average survival of just 14–16 months, joined a trial for DOC1021, an individualized dendritic cell vaccine made from her own tumour to train her immune system to fight back. After surgery, chemotherapy, radiation, and the new therapy, she is now cancer-free for over two years, enjoying tennis and daily life. Phase 1 results showed tumour shrinkage, better survival rates, and minimal side effects. DOC1021, by Diakonos Oncology, is now advancing to phase 2 trials at 20 sites nationwide, offering hope to many facing this aggressive cancer.

👉 Read the full article: Breakthrough in Brain Cancer Treatment: Cell Therapy Beats Deadly Glioblastoma

Disclaimer:

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.